Education
About Us
Working with TipRanks
Follow Us
Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$4.85
-$0.24(-10.17%)
At close: 4:00 PM EST
$4.85
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)2.45M
Market Cap
$308.64M
Enterprise Value-$30.15M
Total Cash (Recent Filing)$227.56M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Mar 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding64,569,970
10 Day Avg. Volume3,908,515
30 Day Avg. Volume2,446,653
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap-0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit85.50
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$14.50Price Target Upside198.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyPhase 2 results showed improved progression-free and overall survival versus standard chemotherapy and included case reports where one patient achieved a complete response and another became eligible for curative-intent surgery, supporting a meaningful therapeutic signal.
Development Strategy And PartnershipsManagement intends to initiate a Phase 3 study of the atebimetinib combination in first-line pancreatic cancer and to launch a trial combining atebimetinib with Regeneron's immune checkpoint inhibitor Libtayo in lung cancer, expanding the program's clinical and commercial opportunities.
Safety ProfileAnalyst highlights a favorable safety profile for the therapy, which supports continued clinical advancement and may improve tolerability compared with earlier MEK inhibitors.
Bears Say
Competitive DifferentiationAnalyst points out uncertainty about how the drug meaningfully differs from a competing therapy, which has reduced investor confidence and pressured the stock.
Evidence RequirementAnalyst emphasizes that similar progression-free results versus the competing therapy mean overall survival data will be required to demonstrate a clear clinical advantage.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $308.64M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Mar 11, 2026 which is in 47 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on Nov 12, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.388 by $0.008.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.31.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,569,970 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.388. Following the earnings report the stock price went down -2.568%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (198.97% Upside)
$14.50 (198.97% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $234.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
153.08%
12-Months-Change
Fundamentals
Return on Equity
-43.75%
Trailing 12-Months
Asset Growth
251.61%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong positive updates, with remarkable clinical trial results and significant financial and strategic developments. While there are some challenges with specific treatments and regulatory timelines, the overall sentiment is positive due to the company's promising progress and future potential.View all IMRX earnings summariesIMRX Stock 12 Month Forecast
Average Price Target
$14.50
▲(198.97% Upside)
Technical Analysis
Ownership Overview
9.41% Insiders
6.71% Mutual Funds
13.36% Other Institutional Investors
62.50% Public Companies and
Individual Investors